SPOTLIGHT -
Phillip S. Low, PhD, Discusses Next Steps in Research of 177Lu-PSMA-617 for mCRPC and Other Cancers
Phillip S. Low, PhD, spoke about what the future holds for treatments like 177Lu-PSMA-617 being developed for patients with prostate cancer.
Medical World News® Inside the Practice: Phillip Low, PhD, on the Development and Approval of Pafolacianine
CancerNetwork® spoke with Phillip Low, PhD, about the development and FDA approval of pafolacianine.
